134 related articles for article (PubMed ID: 16153235)
1. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? results from a pilot study.
Crook TJ; Bramble J
BJU Int; 2005 Oct; 96(6):918; author reply 918-9. PubMed ID: 16153235
[No Abstract] [Full Text] [Related]
2. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.
Jenkins VA; Bloomfield DJ; Shilling VM; Edginton TL
BJU Int; 2005 Jul; 96(1):48-53. PubMed ID: 15963119
[TBL] [Abstract][Full Text] [Related]
3. [Castration of prostate cancer patients and cognition].
Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
[No Abstract] [Full Text] [Related]
4. Researchers probe consequences of androgen deprivation for prostate cancer.
Friedrich MJ
JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787
[No Abstract] [Full Text] [Related]
5. More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer.
Barrass BJ; Thurairaja R; Persad RA
BJU Int; 2004 Jun; 93(9):1175-6. PubMed ID: 15180599
[No Abstract] [Full Text] [Related]
6. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
Boudreaux KJ; Chang SS
BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
[No Abstract] [Full Text] [Related]
7. The benefits of early androgen blockade.
Maroni PD; Crawford ED
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
[TBL] [Abstract][Full Text] [Related]
8. Cognitive effects of hormonal treatment for prostate cancer.
Koupparis A; Ramsden A; Persad R
BJU Int; 2004 May; 93(7):915-6. PubMed ID: 15142135
[No Abstract] [Full Text] [Related]
9. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
Brower V
J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
[No Abstract] [Full Text] [Related]
10. [Quality of life of patients with locally-advanced prostate cancer as a criterium of therapeutic effectiveness].
Kaprin AD; Kostin AA; Tsybul'skiĭ AD
Vopr Onkol; 2009; 55(3):285-90. PubMed ID: 19670727
[No Abstract] [Full Text] [Related]
11. Is hormone ablation still the right choice for advanced prostate cancer?
Fitzpatrick JM
BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
[No Abstract] [Full Text] [Related]
12. Managing complications of androgen deprivation therapy for prostate cancer.
Holzbeierlein JM
Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
[TBL] [Abstract][Full Text] [Related]
13. The role of intermittent androgen deprivation in prostate cancer.
Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
[No Abstract] [Full Text] [Related]
14. Androgen deprivation therapy--managing side effects.
Kabir S; Mancuso P; Rashid P
Aust Fam Physician; 2008 Aug; 37(8):641-6. PubMed ID: 18704213
[TBL] [Abstract][Full Text] [Related]
15. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer.
Pinkawa M; Fischedick K; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Urology; 2006 Jul; 68(1):104-9. PubMed ID: 16806434
[TBL] [Abstract][Full Text] [Related]
16. A review of the use of histrelin acetate in the treatment of prostate cancer.
Crawford ED
BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
[No Abstract] [Full Text] [Related]
17. Androgen deprivation therapy and cognitive impairment?
Bagcchi S
Lancet Oncol; 2015 Jul; 16(7):e314. PubMed ID: 26004374
[No Abstract] [Full Text] [Related]
18. Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen-deprivation therapy.
Hsu CY; Joniau S; Roskams T; Oyen R; Van Poppel H
BJU Int; 2007 Feb; 99(2):311-4. PubMed ID: 17094781
[TBL] [Abstract][Full Text] [Related]
19. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
20. The 'flare' phenomenon: should we be concerned?
Thurairaja R; Persad R; Peters J; Bahl A
BJU Int; 2005 Jul; 96(1):4-6. PubMed ID: 15963110
[No Abstract] [Full Text] [Related]
[Next] [New Search]
